UK
Health analytics
Oncology
Oncology is one of the most dynamic and competitive areas for new therapeutics, with evolving endpoints, biomarker-driven subgroups, and rapidly shifting standards of care, all of which complicate pathway to reimbursement and market access.
It also places a significant burden on patients and health care systems. According to the Global Cancer Observatory, by 2050 the number of new cancer cases per year is expected to rise by 33 million and the number of cancer-related deaths to 18.2 million. Success demands evidence that is not only scientifically robust and also aligned with payer priorities.
At LCP Health Analytics, we combine advanced real-world data analytics with clinical and market access expertise to support oncology innovation
Evidence and strategy to unlock value in oncology
Oncology is a uniquely demanding therapeutic area in practice. Companion diagnostics, precision medicine, surrogate endpoints, data uncertainty, and high-cost therapies introduce new layers of complexity, while payers and Health Technology Assessment (HTA) organizations apply increasingly rigorous evidence standards.
Generating credible, decision-ready insights in this space requires innovative methods, robust analytics, and clear value communication.
What sets us apart is our ability to bridge the gap between clinical and commercial – bringing together deep analytical capability, medical expertise, and market access strategy. We don’t just deliver studies; we deliver decision-ready evidence and market insights that support the development of compelling value narratives that enable oncology medicines to reach patients most in need. We are committed to methodological innovation and excellence as highlighted in our contributions to ENCePP standards and supporting NICE in updating its framework on external validity and transportability methods.
Turning oncology data into payer-ready value
We provide end-to-end expertise across the innovation lifecycle in evidence generation, real-world analytics, health economics, and market access strategy, helping our clients address their global evidence and strategy gaps:
Understanding disease and patient populations
Epidemiology, disease burden, and care pathway mapping to size markets, inform eligible target populations, and identify unmet need.
Designing and executing real-world studies
Retrospective cohorts, registry analyses and target trial emulation, with transparent methods to address bias and confounding. Data landscaping and recommendations to support informed decision making regarding study viability.
Building external comparators
Robust control arms for single-arm trials and label expansions, using propensity methods and indirect comparisons.
Synthesizing the evidence base
Targeted and systematic reviews, meta-analyses and indirect comparisons to define the totality of evidence.
Assessing outcomes and value
Real-world survival and other key endpoints, health care utilization, cost analyses, and patient-reported outcomes (PROs/HRQoL), translated into actionable insights for HTA and payers.
Post-approval RWE including drug safety studies
Post-authorization safety studies and comparative effectiveness.
Demonstrating economic value
Assessment of cost-effectiveness and budget impact, with methods tailored to the treatment’s indication and positioning.
Broader value modeling
Consideration of value beyond the health care system, such as impacts on patient productivity, caregiver burden, and health equity.
Market access and value strategy
Integrated early and throughout product lifecycle commercial planning, value proposition development, communication strategies, channel design as well as patient services tailored to oncology payer challenges.
Innovative reimbursement models
Scenario planning and design of outcomes-based agreements for high-cost oncology treatments.
HTA readiness
JCA strategy, PICO scoping, and alignment of study design with payer and regulatory expectations.
Policy shaping
Articulating the broader narrative around the importance of access for oncology medicines.
Explore our range of services
Real-world evidence generation
We work closely with clients to meet the growing demand for rigorous and impactful real-world evidence.
Health economic outcomes research
We support you in thoroughly evaluating and clearly communicating your product’s value.
Global market access strategy
We help you navigate uncertainty and maximize value across product development and commercialization.
US access solutions
We provide integrated US market access solutions using analytics, clinical insight, and strategic consulting to support pharma success.
Medical and public affairs
We empower medical and public affairs teams to identify and act on opportunities for health system transformation.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Reimagining patient services: The transformative role of Artificial Intelligence and Intelligent Automation in US market access
Explore how AI and IA are transforming US Patient Support Programs by reducing manual workload, streamlining access processes, and improving time-to-therapy.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
